Stocks and Investing
Stocks and Investing
Fri, April 12, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, April 11, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Amsellem Initiated (AQST) at Buy and Held Target at $10 on, Apr 11th, 2024
David Amsellem of Piper Sandler, Initiated "Aquestive Therapeutics, Inc." (AQST) at Buy and Held Target at $10 on, Apr 11th, 2024.
David has made no other calls on AQST in the last 4 months.
There are 5 other peers that have a rating on AQST. Out of the 5 peers that are also analyzing AQST, 0 agree with David's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with David
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $9 on, Friday, April 5th, 2024
- Gary Nachman of "Raymond James" Initiated at Buy and Held Target at $7 on, Thursday, March 28th, 2024
- Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $10 on, Friday, March 15th, 2024
- Thomas Flaten of "Lake Street" Maintained at Strong Buy with Increased Target to $8 on, Thursday, March 7th, 2024
- Andreas Argyrides of "Wedbush" Maintained at Buy with Increased Target to $9 on, Thursday, March 7th, 2024
Contributing Sources